Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

2.560 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Curevac N.V.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
Via ACCESSWIRE
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
Via ACCESSWIRE
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
Via ACCESSWIRE
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
Via Benzinga
CVAC Stock Earnings: CureVac Misses EPS, Misses Revenue for Q4 2023
CVAC stock results show that CureVac missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
3 Stocks to Purge ASAP Before They’re Pulled off Life Support
Here are three stocks to sell now from your portfolio before they run out of cash and collapse. Avoid throwing good money after bad. 
Via InvestorPlace
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Via Benzinga
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Via ACCESSWIRE
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Via ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Via ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
Via ACCESSWIRE
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Via ACCESSWIRE
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
Via Benzinga
CureVac, GS Partner Release Data On Influenza Vaccine Study
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A... 
Via Benzinga
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Via ACCESSWIRE
Why Biopharmaceutical Player CureVac Shares Are Rising Today
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday. 
Via Benzinga
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Via ACCESSWIRE
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company... 
Via Benzinga
Topics Stocks
Exposures US Equities
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
Via ACCESSWIRE
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million. 
Via Benzinga
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.